Hepatoprotective properties of polyprenols were studied in several clinical centers. The study involved 120 patients with various hepatic injuries, which took polyprenols within 3 months. Improvements of blood indicators, increase of activity of the antioxidant system, normalization of liver functions were observed in the patients. The conclusion is that polyprenols are recommended as an active hepatoprotector in chronic injury of the hepatobiliary system of different etiology.
The study was conducted with the participation of 20 patients with non-alcoholic steatohepatitis. They took polyprenols within 12 weeks. There was a significant improvement in the blood indicators that evidenced the reduction of disease activity, normalization of the lipid spectrum, increase of the liver elasticity and reduction of the risk of cirrhosis.
Despite the fact that polyprenols can be widely used for the treatment of diseases associated with viral, bacterial and fungal infections, inflammations and other immune conditions, this article presents new pre-clinical and clinical effects of polyprenols in diseases of the liver and central nervous system. The article was published in English in the journal of "Experimental and Clinical Gastroenterology" 11\2016, author – V. S. Sultanov (Prenolica LTD, Australia), Candidate of Chemical Sciences.Read more...
POLYPRENOLS IN THE TREATMENT VIRAL HEPATITIS
The study involved 120 persons suffering from viral hepatitides of different degrees of severity, as well as alcohol-induced liver injury, cholelithiasis, fatty liver and other diseases of the hepatobiliary system. Some patients received the polyprenolic preparation as a hepatoprotector, the other were given Essentiale. Against the background of administration of polyprenols, such clinical symptoms of liver pathology as weakness, headache, itching, fever, loss of appetite, abdominal pain and others decreased, as well as blood parameters normalized. The improvement occurred much faster, than in the case of treatment with Essentiale.
40 patients with non-alcoholic fatty liver disease participated in the study. All of them were treated with ursodeoxycholic acid, with 19 of them additionally received polyprenols within 3 months. Comparison of results of both groups made it possible to conclude that polyprenols have a high hepatoprotective effect in the treatment of patients with chronic liver injury. In addition, they have a positive influence on the immune status, especially on the cellular component of the immune system.